Barbie's first doll with Type 1 diabetes comes complete with accurate glucose monitor, insulin pump
Mattel announced the release of the first-ever Barbie doll with type 1 diabetes, complete with a continuous glucose monitor and an insulin pump in Barbie's signature pink.
a
5 Mattel released the first Barbie with type 1 diabetes.
Mattel
'Introducing a Barbie doll with type 1 diabetes marks an important step in our commitment to inclusivity and representation,' Krista Berger, Senior Vice President of Barbie and Global Head of Dolls, said in a statement.
'Barbie helps shape children's early perceptions of the world, and by reflecting medical conditions like T1D, we ensure more kids can see themselves in the stories they imagine and the dolls they love.'
5 The new doll is part of the brand's inclusive Fashionistas line, which allows more children to see themselves reflected in Barbie and encourages a view beyond their lived experience.
Mattel
Mattel partnered with Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization, to ensure that the doll accurately captured the community and to accurately depict the medical equipment those with the condition may use.
On her arm, the new doll wears a continuous glucose monitor to help manage her type 1 diabetes, held in place with pink heart-shaped medical tape. It also comes with a Barbie phone that displays a CGM app to help track her blood sugar levels — just like the real-life monitors, which track glucose levels 24 hours a day via a sensor under the skin.
Barbie also has an insulin pump attached to her waist that can automatically administer insulin as needed.
5 The color blue and circle print are both nods to global symbols that represent diabetes awareness.
MATTEL/AFP via Getty Images
Mattel even worked with Breakthrough T1D to determine the dress pattern. She wears a blue polka dot top and matching skirt, and the color blue and circle print are both nods to global symbols that represent diabetes awareness.
Of course, the new Barbie also has a purse to carry any essentials on the go, such as type 1 diabetes supplies or snacks.
'It means the world to be part of bringing greater visibility to a condition that affects so many families,' Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, said in a statement.
'It's an honor to work with a brand that shares our commitment to showing children that a life with type 1 diabetes can be full, vibrant, and empowering.'
5 Barbie has an insulin pump attached to her waist.
Mattel
In coordination with the release of the new Barbie with type 1 diabetes, Barbie also honored two global type 1 diabetes advocates, Peloton Instructor Robin Arzón in the US and model Lila Moss in the UK, with their own one-of-a-kind Barbie dolls.
'To be able to now see Barbie dolls with T1D, and to receive a Barbie doll that visibly looks like me even wearing her patches, is both surreal and special,' Moss said.
'It's an absolute honor to receive a Barbie doll as a part of the brand's efforts to grow awareness and representation surrounding type 1 diabetes, so that we can help show kids that all types of challenges give us all the more reason to push forward and achieve our dreams,' Arzón added.
5 On her arm, the new doll wears a continuous glucose monitor to help manage her type 1 diabetes.
Mattel
Type 1 diabetes is a chronic autoimmune condition that causes the pancreas to make little or no insulin, a hormone that allows sugar (glucose) to enter cells to produce energy, ultimately leading to dependence on insulin therapy.
Approximately 1.24 million people in the US live with type 1 diabetes, and that number is expected to grow to 5 million by 2050.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
2 hours ago
Taliban say efforts to release a British couple from Afghan prison not yet complete
ISLAMABAD -- The Taliban said Wednesday that efforts to free a British couple from an Afghan prison are not yet complete and denied that their rights were being violated despite concerns from their families and U.N. officials. Peter and Barbie Reynolds, who are in their 70s, were arrested in early February after being taken from their home in central Bamiyan province to the capital, Kabul. The husband and wife run an organization that provides education and training programs. Family members in the U.K. have said they are being mistreated and held on undisclosed charges. U.N. human rights experts on Monday called for the couple's release, warning their physical and mental health was deteriorating rapidly and that they were at risk of irreparable harm or even death. The Taliban's Foreign Minister Amir Khan Muttaqi rejected concerns about rights violations. 'They are in constant contact with their families,' Muttaqi told reporters at a media briefing in Kabul. 'Consular services are available. Efforts are underway to secure their release. These steps have not yet been completed. Their human rights are being respected. They are being given full access to treatment, contact and accommodation.' He did not say what steps were being taken to secure their release. According to the U.N. experts, the couple's spell in detention included time in a maximum-security facility and later in underground cells, without sunlight, before being moved to above-ground cells at the General Directorate of Intelligence in Kabul. Peter needs heart medication and, during his detention, has had two eye infections and intermittent tremors in his head and down his left arm. He recently collapsed, the experts added, while Barbie suffers from anaemia and remains weak. Officials from the U.K. Foreign Ministry visited the couple on July 17, family members said. Peter and Barbie have no bed or furniture and sleep on a mattress on the floor, the family said in a statement Sunday. Peter's face is red, peeling and bleeding, likely due to the return of skin cancer that urgently needs removing. 'We, their four adult children, have written privately to the Taliban leadership twice, pleading for them to uphold their beliefs of compassion, mercy, fairness, and human dignity," the children added.
San Francisco Chronicle
4 hours ago
- San Francisco Chronicle
Taliban say efforts to release a British couple from Afghan prison not yet complete
ISLAMABAD (AP) — The Taliban said Wednesday that efforts to free a British couple from an Afghan prison are not yet complete and denied that their rights were being violated despite concerns from their families and U.N. officials. Peter and Barbie Reynolds, who are in their 70s, were arrested in early February after being taken from their home in central Bamiyan province to the capital, Kabul. The husband and wife run an organization that provides education and training programs. Family members in the U.K. have said they are being mistreated and held on undisclosed charges. U.N. human rights experts on Monday called for the couple's release, warning their physical and mental health was deteriorating rapidly and that they were at risk of irreparable harm or even death. The Taliban's Foreign Minister Amir Khan Muttaqi rejected concerns about rights violations. 'They are in constant contact with their families,' Muttaqi told reporters at a media briefing in Kabul. 'Consular services are available. Efforts are underway to secure their release. These steps have not yet been completed. Their human rights are being respected. They are being given full access to treatment, contact and accommodation.' He did not say what steps were being taken to secure their release. According to the U.N. experts, the couple's spell in detention included time in a maximum-security facility and later in underground cells, without sunlight, before being moved to above-ground cells at the General Directorate of Intelligence in Kabul. Peter needs heart medication and, during his detention, has had two eye infections and intermittent tremors in his head and down his left arm. He recently collapsed, the experts added, while Barbie suffers from anaemia and remains weak. Officials from the U.K. Foreign Ministry visited the couple on July 17, family members said. Peter and Barbie have no bed or furniture and sleep on a mattress on the floor, the family said in a statement Sunday. Peter's face is red, peeling and bleeding, likely due to the return of skin cancer that urgently needs removing. 'We, their four adult children, have written privately to the Taliban leadership twice, pleading for them to uphold their beliefs of compassion, mercy, fairness, and human dignity," the children added.
Business Wire
6 days ago
- Business Wire
Digostics Announces University Trial of New At-home Type 1 Diabetes Test Underway
OXFORD, England--(BUSINESS WIRE)--Researchers have initiated an evaluation of a new at-home test to diagnose and monitor early stages of type 1 diabetes (T1D), based on blood glucose levels. The test would be used in individuals who have already tested positive for T1D autoantibodies to identify where they may be in their early-stage T1D progression. The trial, which is funded by Breakthrough T1D (formerly JDRF) the leading global T1D research and advocacy organization, will assess the accuracy, reproducibility, and acceptability of the GTT@home Oral Glucose Tolerance Test (OGTT) compared to in-clinic OGTTs. The results of the trial will inform future regulatory submissions for GTT@home use in T1D, which already has regulatory approval in the UK, Europe and other regions for other types of diabetes. GTT@home is an OGTT developed by British diabetes home-testing company Digostics that uses finger-prick blood samples to measure how well the body processes glucose. The test, being studied at Yale School of Medicine in New Haven, Conn., has been shown to be as accurate as lab-based OGTTs when used in adults with glucose intolerance, type 2 diabetes, or in pregnant individuals to diagnosis gestational diabetes. The GTT@home test has successfully been implemented in several UK NHS Trusts to screen for gestational diabetes in pregnancy. Dr. Jennifer Sherr, Professor of Pediatric Endocrinology and the Medical Director of Pediatric Diabetes at Yale School of Medicine and co-lead principal investigator of the trial, said: 'As the presence of diabetes autoantibodies foretells an eventual diagnosis of T1D, it is critical to conduct an OGTT to stage the disease, which helps predict the risk of progression over time. Yet, in the current paradigm this requires coming to a clinical center or laboratory and getting venous blood draws. Despite knowing there is an increased risk of diabetes many individuals struggle to undergo an OGTT for staging, or repeat the test to permit ongoing monitoring. An at-home OGTT would alleviate this barrier. The ability to have those at risk use a product that is simple, requires fingerpricks instead of venous draws, and can be done within a person's own home at a date and time that is convenient for them would be a fantastic step forward for both patients and providers.' T1D can be diagnosed at any age, and it is the most common childhood autoimmune disease, affecting around one in 350 children. In T1D the body's immune system attacks and destroys the insulin-producing cells in the pancreas, resulting in elevated blood glucose levels. It affects every aspect of health and well-being and results in lifelong insulin dependence and an increased risk of major health problems such as heart disease, blindness, and kidney failure. In 40% or more of children the diagnosis of T1D is not made until the child has become severely unwell and presents with metabolic decompensation, which is known as diabetic ketoacidosis (DKA), a life-threatening diabetes complication. Dr. Raquel Lopez-Diez, Scientist at Breakthrough T1D commented, 'Breakthrough T1D is excited to fund this important work with Yale University School of Medicine to explore an at-home alternative to OGTT for glycemic monitoring in the early stages of type 1 diabetes. Traditional in-clinic OGTTs are time-consuming, can be challenging to navigate for younger individuals, and require significant clinic resources. As new therapies emerge that can delay and, hopefully, one day prevent the progression of type 1 diabetes, it is critical to have the tools to accurately and reliably monitor and diagnose the early stages of the disease. A validated at-home testing approach would represent a major breakthrough. We look forward to seeing the results of this important study.' T1D develops in stages over time, and early stages can be detected through a simple blood test. In stage 1 the body develops islet autoantibodies but the blood glucose levels are still normal. In stage 2, islet autoantibodies are present and individuals experience abnormal blood glucose or dysglycemia, and by stage 3 an individual has the clinical diagnosis of T1D and symptoms may begin to appear due to significant loss of insulin-producing cells. The OGTT is the gold-standard test recommended for defining the stage of T1D a person is experiencing, and it is the most sensitive test for monitoring T1D stages 1 and 2. Hospital-based OGTTs are often not well tolerated because they require placement of an intravenous line inserted into the vein or multiple blood draws, as several blood samples taken over 2-hours in a healthcare setting. Study lead Dr. Alfonso Galderisi, Associate Professor of Pediatrics at Yale School of Medicine, confirmed that the study will recruit 60 patients aged eight and over. 'To understand the ease of conducting the test, participants will complete an unsupervised GTT@home test. Five to seven days later, participants will come to our research unit and we will conduct the standard of care OGTT alongside a supervised GTT@home, with the results of the two tests compared to assess accuracy. We will also be interviewing participants to assess their perception of the two methods used to conduct OGTTs.' Glucose tolerance tests are performed in the morning after an overnight fast. The GTT@home test kit contains the test device, finger prickers for blood sample collection, a preformulated glucose drink, and detailed instructions. The process begins with an initial finger prick blood sample, followed by the consumption of the glucose drink. Two hours later, a second blood sample is taken. With standard clinic-based OGTTs, individuals need to travel to a clinic early in the morning and then undergo the two blood draws two hours apart and have an IV inserted. The GTT@home device analyses blood samples shortly after completion of the test and shares results in a timely manner directly with the study teams or clinician. Expedited analysis of samples eliminates the risk of sample degradation that can affect hospital-based OGTTs when samples are not sent to the lab immediately, improving diagnostic reliability. "The support from Breakthrough T1D and the team at Yale School of Medicine underscores once again the huge potential for our at-home OGTT for use in T1D," said James Jackson, CEO and Founder of Digostics. "We are working closely with the Yale study team to support this trial.'
